Reviewing Amgen Inc. (AMGN)’s and BioSpecifics Technologies Corp. (NASDAQ:BSTC)’s results

Amgen Inc. (NASDAQ:AMGN) and BioSpecifics Technologies Corp. (NASDAQ:BSTC), both competing one another are Biotechnology companies. We will contrast their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Amgen Inc. 23.75B 5.06 8.39B 12.13 16.01
BioSpecifics Technologies Corp. 29.81M 16.67 16.51M 2.40 25.59

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Amgen Inc. and BioSpecifics Technologies Corp. BioSpecifics Technologies Corp. appears to has lower revenue and earnings than Amgen Inc. Company that presently has a lower P/E ratio means that it is the more affordable of the two businesses. Amgen Inc.’s presently lower P/E ratio means it is more affordable than BioSpecifics Technologies Corp.

Profitability

Table 2 shows us the net margins, return on assets and return on equity of both businesses.

Net Margins Return on Equity Return on Assets
Amgen Inc. 35.33% 12.6% 3.1%
BioSpecifics Technologies Corp. 55.38% 21.8% 20.7%

Risk and Volatility

Amgen Inc.’s 1.42 beta indicates that its volatility is 42.00% more volatile than that of Standard and Poor’s 500. BioSpecifics Technologies Corp. on the other hand, has 1.46 beta which makes it 46.00% more volatile compared to Standard and Poor’s 500.

Liquidity

The Current Ratio and a Quick Ratio of Amgen Inc. are 3.1 and 2.8. Competitively, BioSpecifics Technologies Corp. has 48.4 and 48.4 for Current and Quick Ratio. BioSpecifics Technologies Corp.’s better ability to pay short and long-term obligations than Amgen Inc.

Dividends

Amgen Inc. pays out an annual dividend of $5.28 per share while its dividend yield is 2.8%. No dividend is paid out by BioSpecifics Technologies Corp.

Analyst Ratings

The table delivered features the ratings and recommendations for Amgen Inc. and BioSpecifics Technologies Corp.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Amgen Inc. 0 3 1 2.25
BioSpecifics Technologies Corp. 0 0 0 0.00

Amgen Inc.’s upside potential currently stands at 12.71% and an $215 average price target.

Institutional & Insider Ownership

Amgen Inc. and BioSpecifics Technologies Corp. has shares owned by institutional investors as follows: 79.9% and 59.3%. Amgen Inc.’s share owned by insiders are 0.1%. Competitively, insiders own roughly 19.6% of BioSpecifics Technologies Corp.’s shares.

Performance

Here are the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Amgen Inc. -6.8% -1.79% -4.15% 5.14% 11.57% 11.61%
BioSpecifics Technologies Corp. 0.07% -3.28% 5.15% 43.88% 42.55% 41.73%

For the past year Amgen Inc. was less bullish than BioSpecifics Technologies Corp.

Summary

On 9 of the 15 factors BioSpecifics Technologies Corp. beats Amgen Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The companyÂ’s products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Erenumab for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; AMJEVITA to treat psoriatic arthritis and polyarticular juvenile idiopathic arthritis, as well as ankylosing spondylitis and rheumatoid arthritis; ABP 215 for biosimilar candidates; and ABP 980 to treat human epidermal growth factor receptor 2-positive early breast cancer. The companyÂ’s marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; Array BioPharma Inc.; Syngene International Limited; and CytomX Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of DupuytrenÂ’s contracture and PeyronieÂ’s disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.

"

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.